The Science First

Vanderbilt University Medical Center published the largest study of 'super-agers' ever conducted on January 16, 2026, in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

The dataset: 18,080 participants from eight national aging cohorts, sourced from the Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium.

The definition of a 'super-ager' matters here. These are people 80 years or older whose memory performance equals or beats the average for healthy adults aged 50 to 64. Decades younger, cognitively speaking.

Leslie Gaynor, assistant professor of Medicine in Vanderbilt's Division of Geriatric Medicine, co-led the study with statistical genetic analyst Alaina Durant. The findings centered on two genes central to Alzheimer's risk.

Two Genes. One You Want. One You Don't.

The gene nobody wants is APOE-ε4 — the single greatest genetic risk factor for late-onset Alzheimer's disease. The gene you DO want is APOE-ε2, which appears to protect against it.

Super-agers were 68% less likely to carry APOE-ε4 compared to people 80+ who have Alzheimer's dementia, according to the Vanderbilt Health news release.

Superisingly, super-agers were 19% less likely to carry the bad gene even compared to cognitively normal people in the same age group. Not just healthier than sick people — healthier than the healthy.

Flipping to the protective gene, APOE-ε2. Super-agers were 28% more likely to carry it than cognitively normal 80+ controls, and 103% more likely — double — compared to people with Alzheimer's dementia in the same age bracket.

"This was our most striking finding," Gaynor said. The data suggests super-agers aren't just lucky seniors who exercised and ate their vegetables. Their fundamental biology is operating differently.

What the Media Coverage Is Getting Wrong

Fox News ran a piece framing this as a 'longevity gene' that 'boosts DNA repair.' That's partially right but muddies the specific finding. The study is NOT primarily about DNA repair mechanisms. It's about APOE gene variant frequency in a population — specifically who carries which version of this one gene and how dramatically that predicts cognitive resilience.

The 'DNA repair' angle comes from a separate but related line of Alzheimer's research. Conflating them makes the science fuzzier than it is.

New Atlas, covering the same Vanderbilt paper on January 22, 2026, was more precise: the researchers found 'clear genetic evidence that their fundamental biology is playing a big part in living healthier for longer,' per reporter Bronwyn Thompson. That framing is more accurate.

This study included multiple race and ethnicity groups — 1,412 non-Hispanic white super-agers and 211 non-Hispanic Black super-agers among others. Most aging research has historically skewed heavily white. This dataset is more representative, making the findings more robust.

The Political Reality — and the Poll That Should Wake Congress Up

Meanwhile, a survey conducted by Fabrizio Ward — one of the top polling firms in the country and a primary firm for Trump — found strong voter sentiment on Alzheimer's.

Numbers, per the Breitbart report citing the full Fabrizio Ward survey memo:

• 87% of voters say fighting Alzheimer's should be a national priority
• 79% are more likely to back a candidate who prioritizes early detection and treatment access
• 89% say Medicare and private insurer coverage restrictions are blocking patients from FDA-approved treatments
• 92% support the Alzheimer's Screening and Prevention Act (ASAP Act), which would let Medicare cover new FDA-cleared blood tests for Alzheimer's screening

These numbers cross party lines. 78% of independents back better access to early diagnosis. This isn't a partisan issue — it just gets treated like one because health care always becomes a political football.

Charles Sauer, founder and president of The Market Institute, put it plainly: "Voters have no patience for government bureaucrats and insurance companies repeatedly delaying, denying, or complicating access to FDA-approved tools that detect Alzheimer's early, when it's most treatable."

The ASAP Act would specifically let Medicare cover future FDA-cleared blood tests that screen for Alzheimer's. Blood tests. Not experimental surgery. Not unproven therapies. Straightforward diagnostic tools that doctors already want to use.

The Gap Between What We Know and What Patients Can Access

Science is identifying the genetic markers of who's at risk and who's resilient. The FDA has approved diagnostic tools. Blood tests exist. Treatments are improving.

And patients are still getting blocked by Medicare coverage rules and insurance denials.

Approximately 6.9 million Americans are currently living with Alzheimer's disease, according to the Alzheimer's Association — a number projected to nearly double by 2060. The economic burden runs into the hundreds of billions of dollars annually.

Early detection changes outcomes. Yet the coverage infrastructure hasn't caught up to the science.

What This Means for Regular People

If you have a parent or grandparent over 80, this research tells you something useful: cognitive decline is NOT inevitable. Genetics plays a real, measurable role — and understanding those genetics is the first step toward targeted prevention.

If you're a voter, the polling is clear. Any candidate who actually campaigns on Alzheimer's access reform — by name, specifically — is picking up a broadly popular issue that nobody is owning.

If you're a patient right now, the system is still failing you. FDA-approved tests your doctor wants to order are getting denied. The problem is policy, not science, and Congress has a bill sitting in committee that could fix it.